428 related articles for article (PubMed ID: 16226704)
1. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.
She QB; Solit DB; Ye Q; O'Reilly KE; Lobo J; Rosen N
Cancer Cell; 2005 Oct; 8(4):287-97. PubMed ID: 16226704
[TBL] [Abstract][Full Text] [Related]
2. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
3. Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival.
Li Y; Tennekoon GI; Birnbaum M; Marchionni MA; Rutkowski JL
Mol Cell Neurosci; 2001 Apr; 17(4):761-7. PubMed ID: 11312610
[TBL] [Abstract][Full Text] [Related]
4. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.
Paez J; Sellers WR
Cancer Treat Res; 2003; 115():145-67. PubMed ID: 12613196
[No Abstract] [Full Text] [Related]
5. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway.
Wan X; Yokoyama Y; Shinohara A; Takahashi Y; Tamaya T
Cell Death Differ; 2002 Apr; 9(4):414-20. PubMed ID: 11965494
[TBL] [Abstract][Full Text] [Related]
6. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori Y; Kigawa J; Itamochi H; Shimada M; Takahashi M; Kamazawa S; Sato S; Akeshima R; Terakawa N
Clin Cancer Res; 2001 Apr; 7(4):892-5. PubMed ID: 11309338
[TBL] [Abstract][Full Text] [Related]
7. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt.
Fernando RI; Wimalasena J
Mol Biol Cell; 2004 Jul; 15(7):3266-84. PubMed ID: 15121878
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.
Davies MA; Lu Y; Sano T; Fang X; Tang P; LaPushin R; Koul D; Bookstein R; Stokoe D; Yung WK; Mills GB; Steck PA
Cancer Res; 1998 Dec; 58(23):5285-90. PubMed ID: 9850049
[TBL] [Abstract][Full Text] [Related]
9. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
10. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
11. [PTEN expression in endometrial cancer and the prognosis].
Kanamori Y; Uegaki K; Kigawa J; Terakawa N
Nihon Rinsho; 2004 Oct; 62 Suppl 10():406-9. PubMed ID: 15535277
[No Abstract] [Full Text] [Related]
12. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
13. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
14. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells.
Nielsen-Preiss SM; Silva SR; Gillette JM
J Cell Biochem; 2003 Dec; 90(5):964-75. PubMed ID: 14624456
[TBL] [Abstract][Full Text] [Related]
15. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
Whang YE; Yuan XJ; Liu Y; Majumder S; Lewis TD
Vitam Horm; 2004; 67():409-26. PubMed ID: 15110188
[TBL] [Abstract][Full Text] [Related]
16. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
17. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
18. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
19. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.
Altomare DA; You H; Xiao GH; Ramos-Nino ME; Skele KL; De Rienzo A; Jhanwar SC; Mossman BT; Kane AB; Testa JR
Oncogene; 2005 Sep; 24(40):6080-9. PubMed ID: 15897870
[TBL] [Abstract][Full Text] [Related]
20. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
